Tailor Made Compounding
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as pleas October 2020; sentenced February 24, 2021. Evidence tier: Official or peer-reviewed record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
Tailor Made Compounding, a Nicholasville, Kentucky pharmacy, pleaded guilty to distributing unapproved new drugs, and its owner Jeremy Delk pleaded guilty to unlicensed wholesale distribution of a prescription drug. The pharmacy forfeited $1,788,906.82.
According to the Justice Department, the pharmacy’s plea covered distribution of unapproved new drugs from October 25, 2018 through April 1, 2020: SARMs and, under the plea agreement, BPC 157, Cerebrolysin, CJC 1295, DSIP, Epitalon, GW 501516, Ipamorelin, LGD-4033, LL-37, Melanotan II, MK 677, PEG-MGF, Selank and Semax. The forfeiture of $1,788,906.82 represents its 2019 sales of those products. Delk’s plea concerned bulk shipments of methylcobalamin to a California clinic without patient-specific prescriptions. Both pleaded guilty in October 2020.
On February 24, 2021, Judge Gregory F. Van Tatenhove sentenced the pharmacy to three years’ probation. Delk received three years’ probation including four months’ home incarceration, 100 hours of community service, a $20,000 fine, and a prohibition from participating in a business involving the distribution of prescription drugs.
Why it matters: it is the earliest federal case in this archive, and it shows a licensed compounding pharmacy prosecuted over peptides that research-chemical sellers also offer.
Evidence tier: Official or peer-reviewed record.
Sources: DOJ Eastern District of Kentucky sentencing release, February 24, 2021.